The preventive effects of ascorbic acid supplementation on locomotor and acetylcholinesterase activity in an animal model of schizophrenia induced by ketamine

Anais Da Academia Brasileira De Ciências
Louyse S DamazioAlexandra I Zugno

Abstract

Studies have shown that schizophrenic patients seem to have nutritional deficiencies. Ascorbic acid (AA) has an important antioxidant effect and neuromodulatory properties. The aim of this study was to evaluate the effects of AA on locomotor activity and the acetylcholinesterase activity (AChE) in an animal model of schizophrenia (SZ). Rats were supplemented with AA (0.1, 1, or 10 mg/kg), or water for 14 days (gavage). Between the 9th and 15th days, the animals received Ketamine (Ket) (25 mg/kg) or saline (i.p). After the last administration (30 min) rats were subjected to the behavioral test. Brain structures were dissected for biochemical analysis. There was a significant increase in the locomotor activity in Ket treated. AA prevented the hyperlocomotion induced by ket. Ket also showed an increase of AChE activity within the prefrontal cortex and striatum prevented by AA. Our data indicates an effect for AA in preventing alterations induced by Ket in an animal model of SZ, suggesting that it may be an adjuvant approach for the development of new therapeutic strategies within this psychiatric disorder.

References

Aug 16, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·B K Lipska, D R Weinberger
Mar 7, 2001·Antioxidants & Redox Signaling·J Smythies
Apr 3, 2001·Nature Reviews. Neuroscience·H Soreq, S Seidman
Jan 10, 2002·The Journal of Clinical Psychiatry·C W Popper
Jul 3, 2003·Schizophrenia Research·Ravinder ReddyJeffrey K Yao
Jul 1, 1961·Biochemical Pharmacology·G L ELLMANR M FEATHER-STONE
Oct 31, 2003·The New England Journal of Medicine·Robert Freedman
Dec 14, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Axel Becker, Gisela Grecksch
Aug 9, 2005·The Journal of Surgical Research·A RümelinU Fauth
Oct 3, 2006·Current Opinion in Neurobiology·Michael E Hasselmo
Jan 30, 2007·Journal of Psychopharmacology·James M StoneLyn S Pilowsky
May 15, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ricardo W BinfaréAna Lúcia S Rodrigues
May 21, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Larissa de OliveiraAlexandra I Zugno
Oct 28, 2009·Progress in Neurobiology·Urs Meyer, Joram Feldon
Jan 8, 2010·CNS & Neurological Disorders Drug Targets·T T MoneyB Dean
Feb 16, 2010·Comprehensive Psychiatry·Audrey Baguelin-PinaudFlorence Thibaut
Jan 29, 2011·Oxidative Medicine and Cellular Longevity·Leila CaneverAlexandra I Zugno
Feb 1, 2011·Neuropharmacology·Kazu NakazawaJuan E Belforte
Feb 15, 2011·Neuropharmacology·Detlev BoisonBenjamin K Yee
Feb 19, 2011·Metabolic Brain Disease·Larissa de OliveiraAlexandra I Zugno
Jul 13, 2011·Schizophrenia Bulletin·Anouk MarsmanHilleke E Hulshoff Pol
Sep 2, 2011·Biological & Pharmaceutical Bulletin·Taku NagaiKiyofumi Yamada
Sep 1, 2006·Indian Journal of Clinical Biochemistry : IJCB·Gora DadheechPraveen Sharma
Jan 20, 2016·Journal of Chemical Neuroanatomy·Hamid Sepehri, Farzaneh Ganji

❮ Previous
Next ❯

Citations

Mar 16, 2018·CNS Neuroscience & Therapeutics·Stefania Schiavone, Luigia Trabace
Aug 4, 2018·Current Medical Science·Qian-Qian HanJian-Guo Chen
Aug 12, 2020·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·Angelo D SuppAlexandra I Zugno

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.